Insider Transactions in Q1 2021 at Kiniksa Pharmaceuticals, Ltd. (KNSA)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2021
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Indirect |
1,137
-1.35%
|
$26,151
$23.07 P/Share
|
|
Feb 10
2021
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Direct |
1,600
-100.0%
|
$36,800
$23.06 P/Share
|
|
Feb 10
2021
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,600
+50.0%
|
$1,600
$1.59 P/Share
|
|
Feb 09
2021
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Indirect |
23,569
-21.81%
|
$542,087
$23.08 P/Share
|
|
Feb 09
2021
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Direct |
20,401
-100.0%
|
$469,223
$23.04 P/Share
|
|
Feb 09
2021
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,401
+50.0%
|
$20,401
$1.59 P/Share
|
|
Feb 08
2021
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Indirect |
4,528
-4.02%
|
$104,144
$23.0 P/Share
|
|
Feb 08
2021
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Direct |
4,924
-100.0%
|
$113,252
$23.0 P/Share
|
|
Feb 08
2021
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,924
+50.0%
|
$4,924
$1.59 P/Share
|
|
Feb 03
2021
|
Thomas W. Beetham EVP & Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,477
-0.83%
|
$54,494
$22.09 P/Share
|
|
Feb 03
2021
|
Thomas W. Beetham EVP & Chief Legal Officer |
BUY
Conversion of derivative security
|
Direct |
300,000
+50.0%
|
-
|